Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Non-Current Assets for 3 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 12.77% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Dec 2025, down 46.28% year-over-year, with the annual reading at $18.3 million for FY2025, 12.77% down from the prior year.
  • Non-Current Assets for Q4 2025 was $18.3 million at Artiva Biotherapeutics, down from $19.3 million in the prior quarter.
  • The five-year high for Non-Current Assets was $75.0 million in Q3 2024, with the low at $18.3 million in Q4 2025.
  • Average Non-Current Assets over 3 years is $28.3 million, with a median of $21.1 million recorded in 2024.
  • Peak annual rise in Non-Current Assets hit 12.77% in 2025, while the deepest fall reached 74.23% in 2025.
  • Over 3 years, Non-Current Assets stood at $25.3 million in 2023, then fell by 17.17% to $21.0 million in 2024, then fell by 12.77% to $18.3 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $18.3 million, $19.3 million, and $20.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.